more

Cambrex Corporation (CBM)

(Delayed Data from NYSE)

$46.20 USD

+2.73 (6.28%)

Updated May 3, 2019 04:02 PM ET

After-Market: $46.20 (%) 5:22 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank	Definition	Annualized Return
1	Strong Buy	24.03%
2	Buy	17.70%
3	Hold	9.37%
4	Sell	5.03%
5	Strong Sell	2.48%
S&P	500	11.19%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score	A
Growth Score	A
Momentum Score	A
VGM Score	A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

Industry Rank:

Industry: NA

View All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Bet on 4 High-Flying Stocks With Increasing Cash Flows

by Zacks Equity Research Published on December 06,2016

Cash indicates a company's true financial health. It holds the key to its existence, development and success.

Novo Nordisk Files Regulatory Application for Semaglutide

by Zacks Equity Research Published on December 06,2016

Novo Nordisk (NVO) submitted regulatory application for semaglutide in both the U.S. and the EU for the treatment of adults with type II diabetes.

Explosive Returns with the Filtered Zacks Rank 5 Strategy

by Kevin Matras Published on December 06,2016

Kevin Matras goes over the Filtered Zacks Rank 5 strategy. Learn how it can help you pick the best of the Zacks #1 Rank stocks. Highlighted stocks include BGFV, CBM and PLCE.

Zacks.com featured highlights: Aegean Marine Petroleum Network, Cambrex, Gibraltar Industries, State National and Stamps.com

by Zacks Equity Research Published on December 05,2016

Zacks.com featured highlights: Aegean Marine Petroleum Network, Cambrex, Gibraltar Industries, State National and Stamps.com

Alnylam Reports Positive Data on Fitusiran, Givosiran

by Zacks Equity Research Published on December 05,2016

Alnylam (ALNY) announced new positive data from an ongoing phase II OLE study on fitusiran for the treatment of patients with hemophilia A or B, without inhibitors.

Pfizer (PFE) Presents Favorable Data on Leukemia Candidate

by Zacks Equity Research Published on December 05,2016

Pfizer Inc. (PFE) announced new positive data from a randomized phase II study on its investigational candidate glasdegib (PF-04449913) for the first-line treatment of patients with acute myeloid leukemia (AML).

Incyte Jakafi Positive in Pooled Analysis of Five-Year Data

by Zacks Equity Research Published on December 05,2016

Incyte (INCY) announced pooled analysis of five-year data from two phase III studies on Jakafi, which support previous long-term results.

Pfizer Offers Positive Phase III Data on Pediatric Epilesy Drug

by Zacks Equity Research Published on December 02,2016

Pfizer Inc. (PFE) announced positive top-line results from a phase III study evaluating its marketed drug, Lyrica (pregabalin), as adjunctive therapy for the treatment of pediatric patients suffering from epilepsy with partial-onset seizures.

Merck KGaA (MKGAF) Expands Distribution Deal with Roche

by Zacks Equity Research Published on December 02,2016

Merck (MKGAF) announced that it has expanded the distribution alliance with Roche (RHHBY) to include enzyme products ??? PCR and qPCR.

5 Stocks with Solid Net Profit Margin to Bet On

by Zacks Equity Research Published on December 02,2016

Net profit, also referred to as the bottom line, is one of the key tools that gauges the financial health of an enterprise.

AbbVie Crohn's Disease Drug Gets Orphan Drug Status in U.S.

by Zacks Equity Research Published on December 01,2016

AbbVie Inc. (ABBV) announced that the FDA has granted Orphan Drug Designation to its investigational IL-23 inhibitor, risankizumab (ABBV-066; formerly BI 655066), for the treatment of Crohn's disease in pediatric patients.

Achillion, J&J to Initiate Phase IIb Study on HCV Combo

by Zacks Equity Research Published on December 01,2016

Achillion Pharmaceuticals, Inc. (ACHN) announced the initiation of patient dosing in a global phase IIb on JNJ-4178 ??? a triple combination of AL-335, odalasvir (also known as ACH-3102) and J&J's Olysio (simeprevir).

Ultragenyx (RARE) Reports Positive Phase II Study on UX007

by Zacks Equity Research Published on December 01,2016

Ultragenyx (RARE) announced positive data from a phase II study on UX007 for the treatment of patients with long-chain fatty acid oxidation disorder (LC-FAOD).

Agenus' INCAGN1876 in Phase I/II Study for Solid Tumors

by Zacks Equity Research Published on December 01,2016

Agenus (AGEN) announced that it has dosed the first patient in a phase I/II study on INCAGN1949 for the treatment of patients with solid tumors.

Novo Nordisk's Tresiba Shows Safe Cardiovascular Profile

by Zacks Equity Research Published on November 30,2016

Novo Nordisk (NVO) announced headline results from the DEVOTE study that confirmed the cardiovascular safety of Tresiba, in comparison to Sanofi???s (SNY) Lantus.